Literature DB >> 16162609

Can the published cost analysis data for delivery of an efficient primary angioplasty service be applied to the modern National Health Service?

N Melikian1, K Morgan, K J Beatt.   

Abstract

Despite the clinical benefits and safety profile of primary percutaneous coronary intervention (PCI), the health care system in the UK has been slow to adopt this strategy as first line management for ST segment elevation myocardial infarction. The cost implications of a 24 hour a day, seven days per week primary PCI service and the absence of an existing efficient working model within the National Health Service (NHS) framework are two of the major deterrents for provision of such a service. The existent cost effectiveness data for primary PCI is critically reviewed, with particular reference to the NHS.

Entities:  

Mesh:

Year:  2005        PMID: 16162609      PMCID: PMC1769122          DOI: 10.1136/hrt.2004.059402

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  8 in total

Review 1.  Cost-effectiveness of reperfusion strategies.

Authors:  W W Parmley
Journal:  Am Heart J       Date:  1999-08       Impact factor: 4.749

2.  Long term outcome and cost-effectiveness of stenting versus balloon angioplasty for acute myocardial infarction.

Authors:  H Suryapranata; J P Ottervanger; E Nibbering; A W van 't Hof; J C Hoorntje; M J de Boer; M J Al; F Zijlstra
Journal:  Heart       Date:  2001-06       Impact factor: 5.994

3.  Costs of stenting for acute myocardial infarction.

Authors:  A W van 't Hof; H Suryapranata; M J de Boer; J C Hoorntje; F Zijlstra
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321

4.  A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction.

Authors:  M J de Boer; B A van Hout; A L Liem; H Suryapranata; J C Hoorntje; F Zijlstra
Journal:  Am J Cardiol       Date:  1995-10-15       Impact factor: 2.778

5.  Projected cost-effectiveness of primary angioplasty for acute myocardial infarction.

Authors:  T A Lieu; R J Gurley; R J Lundstrom; G T Ray; B H Fireman; M C Weinstein; W W Parmley
Journal:  J Am Coll Cardiol       Date:  1997-12       Impact factor: 24.094

6.  Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators.

Authors:  G W Stone; C L Grines; D Rothbaum; K F Browne; J O'Keefe; P A Overlie; B C Donohue; N Chelliah; R Vlietstra; T Catlin; W W O'Neill
Journal:  J Am Coll Cardiol       Date:  1997-04       Impact factor: 24.094

7.  Hospitalization costs of primary stenting versus thrombolysis in acute myocardial infarction: cost analysis of the Canadian STAT Study.

Authors:  Michel R Le May; Richard F Davies; Marino Labinaz; Heather Sherrard; Jean-François Marquis; Louise A Laramée; Edward R O'Brien; William L Williams; Rob S Beanlands; Graham Nichol; Lyall A Higginson
Journal:  Circulation       Date:  2003-11-03       Impact factor: 29.690

8.  Cost comparison of immediate angioplasty versus thrombolysis followed by conservative therapy for acute myocardial infarction: a randomized prospective trial. Mayo Coronary Care Unit and Catheterization Laboratory Groups.

Authors:  G S Reeder; K R Bailey; B J Gersh; D R Holmes; J Christianson; R J Gibbons
Journal:  Mayo Clin Proc       Date:  1994-01       Impact factor: 7.616

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.